U.S. markets closed

Emerald Health Therapeutics, Inc. (EMHTF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.03430.0000 (0.00%)
At close: 02:11PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0343
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0302 - 0.0349
52 Week Range0.0200 - 0.1310
Avg. Volume86,672
Market Cap7.322M
Beta (5Y Monthly)0.66
PE Ratio (TTM)N/A
EPS (TTM)-0.1240
Earnings DateJul 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for EMHTF

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    Analyst Report: Curaleaf Holdings, Inc.Curaleaf is headquartered in Wakefield, Massachusetts, and cultivates and sells medicinal and recreational cannabis in the U.S. The company has operations in 22 states, including the assets from the Cura Select and Grassroots acquisitions. Its brands include Curaleaf, UKU, Select, and Grassroots. The company acquired EMMAC Life Sciences in March 2021, beginning its foray into the global medical market in competition with Canadian cannabis producers.
    Fair Value
    Economic Moat
    8 days agoMorningstar
View more
  • Newsfile

    Emerald Health Therapeutics, Inc. Provides Update on and Additional Background to Transaction with Skye Bioscience

    Vancouver, British Columbia--(Newsfile Corp. - August 12, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company") is providing an update and additional background on its transaction (the "Transaction") with Skye Bioscience Inc. (OTCQB: SKYE) ("Skye") pursuant to the terms of an arrangement agreement dated May 11, 2022, as amended (the "Arrangement Agreement").On July 28, 2022, Emerald mailed to shareholders of Emerald (the "EHT Shareholders") its manageme

  • Newsfile

    Emerald Health Therapeutics, Inc. Restates Q1 Financial Statements to Meet PCAOB Standard

    Vancouver, British Columbia--(Newsfile Corp. - August 12, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company") announces that it has identified matters which require the Company to make restatements (the "Restatements") in respect of its interim consolidated financial statements for the three months ended March 31, 2022 and 2021 (the "Restated Q1 Financial Statements") and related management discussion and analysis (the "Restated MD&A") relating to (a)

  • CNW Group

    Group of Shareholders Oppose Plan of Arrangement Between Emerald Health Therapeutics and Skye Biosciences Inc.

    Certain shareholders (the "Opposing Shareholders") of Emerald Health Therapeutics Inc. ("Emerald") (CSE: EMH); (OTCQX: EMHTF), announce that they oppose the announced plan of arrangement (the "Plan") between Emerald and Skye Biosciences Inc. ("Skye") (OTCQB: SKYE).